SynthesisFrontiers in medicine2022
Pravastatin in preeclampsia: A meta-analysis and systematic review.
Synthesis in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026.Diabetes care · 2026Guideline
- The role of statins during pregnancy on maternal risk of preeclampsia: a systematic review and meta-analysis.BMC pregnancy and childbirth · 2025Pooled it
- A meta-analysis on first-trimester blood count parameters-is the neutrophil-to-lymphocyte ratio a potentially novel method for first-trimester preeclampsia screening?Frontiers in medicine · 2024Pooled it
- Pravastatin Corrects Endothelial Dysfunction in Ex Vivo Uterine Radial Arteries in Preeclampsia.Acta physiologica (Oxford, England) · 2026Trial
- The Immunopathology of Preeclampsia.Biomedicines · 2026Review
- Early interventions for the prevention of preeclampsia in pregnant women at increased risk: a network meta-analysis.The Cochrane database of systematic reviews · 2026Article
- Oxidative dyslipidemia in early pregnancy: integrating atherogenic index of plasma (AIP) and uric acid (UA) to refine preeclampsia risk stratification.Frontiers in pharmacology · 2026Article
- From empirical regimens to precision prophylaxis: mechanism-based targeting of preeclampsia phenotypes.Frontiers in pharmacology · 2026Review
- Lipid Profile and Management of Dyslipidemias in Pregnancy.Journal of cardiovascular development and disease · 2025Review
- Article
- Infant Viability in Severe Preeclampsia: Management Strategies and the Potential Role of Calprotectin-A Narrative Review.Children (Basel, Switzerland) · 2025Review
- High-sensitivity CRP is elevated in pregnant women with overweight and obesity and modulated by gestational weight gain.Acta obstetricia et gynecologica Scandinavica · 2025Article
- Serum Neuropeptide FFR2 is increased in pregnant women with pre-eclampsia and associated with pregnancy outcomes.Pakistan journal of medical sciences · 2025Article
- Editorial: Latest advancements in organ-on-a-chip technology.Frontiers in pharmacology · 2025Article
- Secondary prevention of preeclampsia.Frontiers in cell and developmental biology · 2025Review
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025.Diabetes care · 2025 · on this mapReview
- Impacts of Maternal Preeclampsia Exposure on Offspring Neuronal Development: Recent Insights and Interventional Approaches.International journal of molecular sciences · 2024Review
- Pravastatin Protects Cytotrophoblasts from Hyperglycemia-Induced Preeclampsia Phenotype.Cells · 2024Article
- Implications of pregnancy on cardiometabolic disease risk: preeclampsia and gestational diabetes.American journal of physiology. Cell physiology · 2024Review
- Understanding the Pathophysiology of Preeclampsia: Exploring the Role of Antiphospholipid Antibodies and Future Directions.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To review of the efficacy and safety of pravastatin use for prophylaxis and treatment of preeclampsia. Design: Systematic review and meta-analysis of clinical studies evaluating pravastatin for treatment and/or prophylaxis of preeclampsia. Data collection: Two independent reviewers systematically searched data from PubMed, Scopus, Web of Science, Cochrane, Embase, and clinicaltrials.gov databases, for studies evaluating pravastatin for prevention of pre-eclampsia. Results: Fourteen studies were identified, including 1,570 pregnant women who received either pravastatin or placebo, published between 2003 and 2022. From these studies, 5 studies were identified for inclusion in the meta-analysis to evaluate the role of pravastatin use prior to 20 weeks of gestation, to prevent pre-eclampsia, Pravastatin treatment reduced the incidence of preeclampsia by 61% and premature birth by 45%. Among the newborns, there was a 45% reduction in intrauterine growth retardation (IUGR) in the treated group, as well as a 77% reduction in those receiving neonatal intensive care unit (NICU) admissions. Conclusion: Prophylactic treatment with pravastatin appears to reduce risk of developing pre-eclampsia as well as potentially lowering risk of IUGR, preterm birth, and NICU admission in neonates.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.